Hasan Herken

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12001673/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of Oxidative Status in Patients Treated with Electroconvulsive Therapy. Clinical Psychopharmacology and Neuroscience, 2017, 15, 40-46.	2.0	10
2	The impact of synapsin III gene on the neurometabolite level alterations after single-dose methylphenidate in attention-deficit hyperactivity disorder patients. Neuropsychiatric Disease and Treatment, 2016, 12, 1141.	2.2	6
3	miR-181b-5p, miR-195-5p and miR-301a-3p are related with treatment resistance in schizophrenia. Psychiatry Research, 2016, 245, 200-206.	3.3	38
4	Association of the Neuropeptide Y LEU7PRO rs16139 and NEUREXIN 3 rs760288 Polymorphisms with Alcohol Dependence. Journal of Microbiology and Biotechnology, 2016, 26, 15-20.	2.1	1
5	Increased urinary 6-hydroxymelatoninsulfate levels in attention deficit hyperactivity disorder diagnosed children and adolescent. Neuroscience Letters, 2016, 617, 195-200.	2.1	9
6	Practice of Acute and Maintenance Electroconvulsive Therapy in the Psychiatric Clinic of a University Hospital from Turkey: between 2007 and 2013. Clinical Psychopharmacology and Neuroscience, 2016, 14, 57-63.	2.0	6
7	The Effect of Single Dose Methylphenidate on Neurometabolites according to COMT Gene Val158Met Polymorphism in the Patient with Attention Deficit Hyperactivity Disorder: A Study Using Magnetic Resonance Spectroscopy. Clinical Psychopharmacology and Neuroscience, 2016, 14, 184-193.	2.0	5
8	Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia. Therapeutic Advances in Psychopharmacology, 2015, 5, 194-207.	2.7	4
9	Association of adult attention deficit hyperactivity disorder subtypes and response to methylphenidate HCL treatment: A magnetic resonance spectroscopy study. Neuroscience Letters, 2015, 604, 188-192.	2.1	3
10	Association of SNAP-25 Gene <i>Dde</i> l and <i>Mnl</i> l Polymorphisms with Adult Attention Deficit Hyperactivity Disorder. Psychiatry Investigation, 2014, 11, 476.	1.6	15
11	Association of VAMP-2 and Syntaxin 1A Genes with Adult Attention Deficit Hyperactivity Disorder. Psychiatry Investigation, 2014, 11, 76.	1.6	22
12	Association of Synapsin III Gene with Adult Attention Deficit Hyperactivity Disorder. DNA and Cell Biology, 2013, 32, 430-434.	1.9	14
13	No Effect of Antidepressant Treatment on Elevated Serum Ceruloplasmin Level in Patients with First-Episode Depression: A Longitidunal Study. Archives of Medical Research, 2012, 43, 294-297.	3.3	12
14	Association between dopamine beta hydroxylase gene polymorphism and age at onset in male schizophrenia. Acta Neuropsychiatrica, 2012, 24, 176-182.	2.1	6
15	The relationship of oxidative metabolism to treatment response in major depression: A biological basis for treatment duration. Neurology Psychiatry and Brain Research, 2012, 18, 15-18.	2.0	6
16	Association Among SNAP-25 Gene <i>Dde</i> I and <i>Mnl</i> I Polymorphisms and Hemodynamic Changes During Methylphenidate Use. Journal of Attention Disorders, 2011, 15, 628-637.	2.6	22
17	CYP1A2*1F Polymorphism Decreases Clinical Response to Clozapine in Patients with Schizophrenia. Journal of Microbiology and Biotechnology, 2011, 21, 93-99.	2.1	17
18	A Defect in the Antioxidant Defense System in Schizophrenia. Neuropsychobiology, 2009, 60, 87-93.	1.9	54

HASAN HERKEN

#	Article	IF	CITATIONS
19	Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 56-60.	1.7	28
20	The Association of Olanzapine-Induced Weight Gain with Peroxisome Proliferator–Activated Receptor-γ2 Pro12Ala Polymorphism in Patients with Schizophrenia. DNA and Cell Biology, 2009, 28, 515-519.	1.9	33
21	High ceruloplasmin levels are associated with obsessive compulsive disorder: a case control study. Behavioral and Brain Functions, 2008, 4, 52.	3.3	18
22	Oxidative imbalance in obsessive compulsive disorder patients: A total evaluation of oxidant–antioxidant status. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 487-491.	4.8	68
23	Role of Oxidative and Antioxidative Parameters in Etiopathogenesis and Prognosis of Panic Disorder. International Journal of Neuroscience, 2008, 118, 1025-1037.	1.6	38
24	Increased Levels of Nitric Oxide, Cortisol and Adrenomedullin in Patients with Chronic Schizophrenia. Medical Principles and Practice, 2007, 16, 137-141.	2.4	84
25	Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1330-1336.	4.8	32
26	The A218C polymorphism of tryptophan hydroxylase gene and migraine. Journal of Clinical Neuroscience, 2007, 14, 249-251.	1.5	9
27	The protective effects of omegaâ^'3 fatty acids against MK-801-induced neurotoxicity in prefrontal cortex of rat. Neurochemistry International, 2007, 50, 196-202.	3.8	51
28	Adenosine Deaminase, Nitric Oxide, Superoxide Dismutase, and Xanthine Oxidase in Patients with Major Depression: Impact of Antidepressant Treatment. Archives of Medical Research, 2007, 38, 247-252.	3.3	274
29	Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: Impact of past episodes. World Journal of Biological Psychiatry, 2006, 7, 51-55.	2.6	115
30	Associations between Mn-SOD genetic polymorphism and schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 761.	4.8	2
31	Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment. Human Psychopharmacology, 2006, 21, 53-59.	1.5	53
32	Lack of association between the 308GA polymorphism of the tumor necrosis factor alpha gene and temporomandibular dysfunction. The Pain Clinic, 2006, 18, 175-180.	0.1	1
33	Association between Ala–9Val polymorphism of Mn-SOD gene and schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 123-131.	4.8	85
34	Monoamine oxidase-A gene promoter polymorphism in temporomandibular joint pain and dysfunction. The Pain Clinic, 2005, 17, 39-44.	0.1	3
35	The –308 G/A polymorphism of tumor necrosis factor alpha gene is not associated with migraine. The Pain Clinic, 2005, 17, 389-393	0.1	6
36	The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 43-47.	3.2	58

HASAN HERKEN

#	Article	IF	CITATIONS
37	Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatology International, 2003, 23, 104-107.	3.0	233
38	Pathophysiological role of nitric oxide and adrenomedullin in autism. Cell Biochemistry and Function, 2003, 21, 55-60.	2.9	65
39	Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene ⋆. European Psychiatry, 2003, 18, 77-81.	0.2	49
40	T102C Polymorphisms at the 5-HT2A Receptor Gene in Turkish Schizophrenia Patients: A Possible Association with Prognosis. Neuropsychobiology, 2003, 47, 27-30.	1.9	14
41	Migraine and angiotensin-converting enzyme association in Turkish patients. The Pain Clinic, 2003, 15, 473-477.	0.1	10
42	Monoamine oxidase-A gene promoter polymorphism in female migraineurs. The Pain Clinic, 2003, 15, 455-458.	0.1	3
43	Significance of catechol-O-methyltransferase gene polymorphism in myofacial pain syndrome. The Pain Clinic, 2003, 15, 309-313.	0.1	7
44	The 1438G/A polymorphism of the 5-HT2Areceptor gene is associated with aura in migraine. The Pain Clinic, 2003, 15, 315-319.	0.1	4
45	Possible Role of Nitric Oxide and Adrenomedullin in Bipolar Affective Disorder. Neuropsychobiology, 2002, 45, 57-61.	1.9	92
46	Significance of Serotonin Transporter Gene 5-HTTLPR and Variable Number of Tandem Repeat Polymorphism in Attention Deficit Hyperactivity Disorder. Neuropsychobiology, 2002, 45, 176-181.	1.9	80
47	The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 995-1005.	4.8	240
48	The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. Journal of Psychiatric Research, 2002, 36, 309-315.	3.1	59
49	Significance of serotonin transporter gene polymorphism in migraine. Journal of the Neurological Sciences, 2001, 186, 27-30.	0.6	69
50	Association of the T102C polymorphism of 5-HT2A receptor gene with aura in migraine. Journal of the Neurological Sciences, 2001, 188, 99-101.	0.6	41
51	Significance of the catechol-O-methyltransferase gene polymorphism in migraine. Molecular Brain Research, 2001, 94, 193-196.	2.3	53
52	Association of T102C polymorphism of the 5-HT2A receptor gene with pyschiatric status in fibromyalgia syndrome. Rheumatology International, 2001, 21, 58-61.	3.0	63
53	Possible association of temporomandibular joint pain and dysfunction with a polymorphism in the serotonin transporter gene. American Journal of Orthodontics and Dentofacial Orthopedics, 2001, 120, 308-313.	1.7	57